8 results match your criteria: "UCSF Center for Translational and Policy Research on Precision Medicine (TRANSPERS)[Affiliation]"

Purpose: Circulating tumor DNA (ctDNA) testing has become a promising tool to guide first-line (1L) targeted treatment for advanced non-small cell lung cancer (aNSCLC). This study aims to estimate the clinical validity (CV) and clinical utility (CU) of ctDNA-based next-generation sequencing (NGS) for oncogenic driver mutations to inform 1L treatment decisions in aNSCLC through a systematic literature review and meta-analysis.

Methods: A systematic literature search was conducted in PubMed/MEDLINE and Embase to identify randomized control trials or observational studies reporting CV/CU on ctDNA testing in patients with aNSCLC.

View Article and Find Full Text PDF

One year of publishing: onward and upward.

Health Aff Sch

July 2024

UCSF Center for Translational and Policy Research on Precision Medicine (TRANSPERS), Department of Clinical Pharmacy, University of California, San Francisco, 490 Illinois St, San Francisco, CA 94143, United States.

View Article and Find Full Text PDF
Article Synopsis
  • * A study of 19 private payers revealed that while many recognize the promise of MCED tests for cancers lacking current screening (84%), there's skepticism for those with established screenings (37%), citing concerns like lack of proven benefits and high false-negative rates.
  • * Most payers are open to accepting real-world evidence instead of traditional randomized controlled trials but fear that MCED might not reduce health disparities and could lead to overtreatment and access barriers.
View Article and Find Full Text PDF

Ten health policy challenges for the next 10 years.

Health Aff Sch

July 2023

Division of Health Policy and Management, School of Public Health, University of Minnesota, Minneapolis, MN 55455, United States.

Health policies and associated research initiatives are constantly evolving and changing. In recent years, there has been a dizzying increase in research on emerging topics such as the implications of changing public and private health payment models, the global impact of pandemics, novel initiatives to tackle the persistence of health inequities, broad efforts to reduce the impact of climate change, the emergence of novel technologies such as whole-genome sequencing and artificial intelligence, and the increase in consumer-directed care. This evolution demands future-thinking research to meet the needs of policymakers in translating science into policy.

View Article and Find Full Text PDF

The Health Inequality Impact of Liquid Biopsy to Inform First-Line Treatment of Advanced Non-Small Cell Lung Cancer: A Distributional Cost-Effectiveness Analysis.

Value Health

December 2023

Department of Clinical Pharmacy, UCSF Center for Translational and Policy Research on Precision Medicine (TRANSPERS), San Francisco, CA, USA; UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA; UCSF Philip R. Lee Institute for Health Policy, San Francisco, CA, USA.

Objectives: To perform a distributional cost-effectiveness analysis of liquid biopsy (LB) followed by, if needed, tissue biopsy (TB) (LB-first strategy) relative to a TB-only strategy to inform first-line treatment of advanced non-small cell lung cancer (aNSCLC) from a US payer perspective by which we quantify the impact of LB-first on population health inequality according to race and ethnicity.

Methods: With a health economic model, quality-adjusted life-years (QALYs) and costs per patient were estimated for each subgroup. Given the lifetime risk of aNSCLC, and assuming equally distributed opportunity costs, the incremental net health benefits of LB-first were calculated, which were used to estimate general population quality-adjusted life expectancy at birth (QALE) by race and ethnicity with and without LB-first.

View Article and Find Full Text PDF

Background: Circulating tumor DNA (ctDNA) is used to select initial targeted therapy, identify mechanisms of therapeutic resistance, and measure minimal residual disease (MRD) after treatment. Our objective was to review private and Medicare coverage policies for ctDNA testing.

Methods: Policy Reporter was used to identify coverage policies (as of February 2022) from private payers and Medicare Local Coverage Determinations (LCDs) for ctDNA tests.

View Article and Find Full Text PDF

CMS Coverage With Evidence Development-Challenges and Opportunities for Improvement.

JAMA Health Forum

September 2022

UCSF Center for Translational and Policy Research on Precision Medicine (TRANSPERS), Department of Clinical Pharmacy, Philip R. Lee Institute for Health Policy Studies, University of California, San Francisco.

View Article and Find Full Text PDF